Mick Farrell’s father questioned his son’s double degree from MIT when he didn’t immediately see the opportunity facing the sleep apnea company. But the younger Farrell quickly came around and helped build ResMed into a $15 billion company, with the last five years at the helm as CEO. Today, however, Farrell has ResMed beginning to take a very different path, migrating away from pure medical device sales and into selling software and other tech services to physicians.
Mick Farrell was appointed ResMed’s CEO in March 2013. He joined ResMed in 2000, serving as president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and senior roles in marketing and business development.
Before joining ResMed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Genzyme Corporation (now part of Sanofi), The Dow Chemical Company and BHP Billiton.
Mick serves as board director at ResMed, the Advanced Medical Technology Association (AdvaMed) and Zimmer Biomet (NYSE: ZBH), and volunteer trustee for UC San Diego Foundation, Rady Children’s Hospital, the La Jolla Playhouse, and the Museum of Man in San Diego.
Mick holds a Master’s in chemical engineering and an MBA, both from the Massachusetts Institute of Technology, and a bachelor’s in engineering with first-class honors from the University of New South Wales.
Meet Our Host
Healthegy Contributing Host Stephen Krupa is CEO of Healthedge, a software company focused on providing next-generation, business-transforming technology products to the healthcare payor market.